ZJJF(SH:600668) Shang Hai Zheng Quan Bao·2025-07-29 17:44Core Viewpoint - Zhejiang Jianfeng Group's subsidiary, Jianfeng Pharmaceutical, has received approval for the listing of the chemical raw material drug, Empagliflozin, indicating compliance with national standards for raw material drug evaluation and enabling sales in the domestic market, which will help expand the subsidiary's business scope [2][5]. Group 1: Drug Approval and Details - The chemical raw material drug approved is Empagliflozin, with a packaging specification of 10kg per barrel, and the approval notification number is 2025YS00624 [2][3]. - The approval is valid until July 24, 2030, and the registration standard number is YBY66992025 [3]. Group 2: Drug Development and Investment - Empagliflozin is an SGLT2 inhibitor used as an adjunct treatment for improving blood sugar control in adult patients with type II diabetes, functioning by blocking glucose reabsorption in the kidneys [3][4]. - The total investment in the development of the Empagliflozin raw material project is approximately RMB 8.8769 million [4]. Group 3: Impact on the Company - The approval of Empagliflozin signifies that Jianfeng Pharmaceutical has the necessary production capabilities, which will facilitate the expansion of its business in the pharmaceutical sector [5].